Stratasys (SSYS) Announces Changes to Board of Directors

Stratasys Ltd. (Nasdaq: SSYS) (“Stratasys” or the “Company”), a leader in polymer 3D printing solutions, today announced that it has appointed Aris Kekedjian as an independent member of the Company’s Board of Directors, effective immediately. Mr. Kekedjian replaces Ziva Patir, who has decided to step down from the Company’s Board following ten years of service as a director. With this appointment, the Board will continue to comprise eight directors, seven of whom are independent.

Mr. Kekedjian is an established executive who brings more than 30 years of leadership expertise across business development, M&A and operations of complex cross-border businesses at scale. He currently serves as Chairman and Chief Executive Officer of Trinity Biotech, a publicly-traded healthcare diagnostics platform focused on the development, manufacture and marketing of clinical diagnostic products. Prior to Trinity, he spent three decades at General Electric and GE Capital in various leadership roles, most recently serving as Head of Business Development and Chief Investment Officer.

“Ongoing refreshment is a priority for our Board, and we are pleased to welcome Aris to the Stratasys Board,” said Dov Ofer, Stratasys’ Chairman of the Board of Directors. “With Aris’ global business experience, financial expertise and proven ability to deliver transformation of business, we are confident that Stratasys will benefit from his input and guidance as we continue to advance on our strategic initiatives and review opportunities to further enhance shareholder value.”

“I have long-admired Stratasys’ innovation and leadership in additive manufacturing, and I am honored to join Stratasys at such an important time for the Company,” said Mr. Kekedjian. “I look forward to working collaboratively with the Board and management team to drive the Company’s success and deliver value for shareholders.”

Ofer added, “On behalf of the Board, we thank Ziva for her outstanding service and many contributions to the Stratasys Board over the past ten years. Ziva was instrumental in enhancing Stratasys’ ongoing ESG programs, which are some of the first and most advanced in our industry. We wish her all the best.”

“It has been an honor to serve on the Stratasys Board for the past decade,” said Ms. Patir. “I am confident that the Company is well-positioned for continued growth under the oversight of this talented Board, and I look forward to watching the Company’s future successes.”

About Aris Kekedjian

Aris Kekedjian currently serves as Chairman and Chief Executive Officer of Trinity Biotech. Prior to joining Trinity Biotech in October 2022, he served as President and Chief Executive Officer of Icahn Enterprises from April 2021 to January 2022. Prior to that, Mr. Kekedjian held various roles of increasing responsibility at General Electric and GE Capital from 1989 to 2019, including Head of Corporate Development and Chief Investment Officer of GE; Managing Director and Global Head, Business Development of GE Capital; and Managing Director, Global Corporate Development and CEO of GE Capital in the MEA region. During his tenure at GE and GE Capital, Mr. Kekedjian guided the company through multiple phases of growth and transformation, including through the 2008 financial crisis and a series of multibillion-dollar mergers that helped reposition disparate assets into leading businesses. In addition, he previously served as a director of Xerox Holdings Corporation and XPO Logistics. Mr. Kekedjian holds a Bachelor of Commerce degree in Finance and International Business from Concordia University in Montreal, Canada.

You May Also Be Interested In

• XORTX board chairman Anthony Giovinazzo resigns
• Heritage Global to wind down specialty lending unit, expects material charge
• BCE names Rebecca McKillican to board as Katherine Lee retires